clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Endometriosis D004715 29 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Ergotism D004881 4 associated lipids
Erythema Nodosum D004893 5 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Exanthema D005076 11 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Fistula D005402 8 associated lipids
Foot Diseases D005534 4 associated lipids
Fractures, Open D005597 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Gastritis D005756 27 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Giardiasis D005873 3 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Hand Dermatoses D006229 5 associated lipids
Hearing Disorders D006311 10 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Heart Failure D006333 36 associated lipids
Hemolysis D006461 131 associated lipids
Hemophilia A D006467 10 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hernia, Hiatal D006551 3 associated lipids
HIV Seropositivity D006679 15 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hypoproteinemia D007019 1 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Influenza, Human D007251 11 associated lipids
Insulin Resistance D007333 99 associated lipids
Iris Diseases D007499 2 associated lipids
Iritis D007500 2 associated lipids
Ischemia D007511 18 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Klebsiella Infections D007710 7 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Leprosy D007918 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kuwayama H et al. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. 2007 Aliment. Pharmacol. Ther. pmid:17439512
Van Oijen AH et al. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. 2000 Aliment. Pharmacol. Ther. pmid:10930892
Hurenkamp GJ et al. Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. 2000 Aliment. Pharmacol. Ther. pmid:10930901
Wong BC et al. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. 2001 Aliment. Pharmacol. Ther. pmid:11380322
Nada T et al. DNA typing for Helicobacter pylori isolates from eradication-failed patients: comparison of the isolates before and after therapy. 2004 Aliment. Pharmacol. Ther. pmid:15298604
Kaneko F et al. High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. 2004 Aliment. Pharmacol. Ther. pmid:15298607
de Francesco V et al. Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. 2006 Aliment. Pharmacol. Ther. pmid:16423002
Lamouliatte H et al. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. 1999 Aliment. Pharmacol. Ther. pmid:10571611
Wong WM et al. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. 2002 Aliment. Pharmacol. Ther. pmid:11929398
Park HG et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. 2012 Aliment. Pharmacol. Ther. pmid:22066530
Kim JS et al. Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. 2002 Aliment. Pharmacol. Ther. pmid:11860410
Isomoto H et al. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. 2000 Aliment. Pharmacol. Ther. pmid:11121910
Canducci F et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. 2000 Aliment. Pharmacol. Ther. pmid:11121911
Pilotto A et al. Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. 1996 Aliment. Pharmacol. Ther. pmid:8971305
Gisbert JP et al. Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. 2006 Aliment. Pharmacol. Ther. pmid:16556172
Kawabata H et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. 2003 Aliment. Pharmacol. Ther. pmid:12534411
Catalano F et al. Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. 2000 Aliment. Pharmacol. Ther. pmid:11012478
Gomollón F et al. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. 2000 Aliment. Pharmacol. Ther. pmid:11012479
De Francesco V et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. 2004 Aliment. Pharmacol. Ther. pmid:14871280
Koivisto TT et al. First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. 2005 Aliment. Pharmacol. Ther. pmid:15771764